AU2015202413B2 - Method for the preparation of human albumin with reduced level of dissolved oxygen - Google Patents

Method for the preparation of human albumin with reduced level of dissolved oxygen Download PDF

Info

Publication number
AU2015202413B2
AU2015202413B2 AU2015202413A AU2015202413A AU2015202413B2 AU 2015202413 B2 AU2015202413 B2 AU 2015202413B2 AU 2015202413 A AU2015202413 A AU 2015202413A AU 2015202413 A AU2015202413 A AU 2015202413A AU 2015202413 B2 AU2015202413 B2 AU 2015202413B2
Authority
AU
Australia
Prior art keywords
albumin
solution
stage
dissolved oxygen
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015202413A
Other languages
English (en)
Other versions
AU2015202413A1 (en
Inventor
Montserrat Costa Rierola
Juan Ignacio Jorquera Nieto
Ana Maria Ortiz Fernandez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Grifols SA
Original Assignee
Grifols SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52003454&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2015202413(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Grifols SA filed Critical Grifols SA
Publication of AU2015202413A1 publication Critical patent/AU2015202413A1/en
Application granted granted Critical
Publication of AU2015202413B2 publication Critical patent/AU2015202413B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76Albumins
    • C07K14/765Serum albumin, e.g. HSA
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38Albumins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/06Free radical scavengers or antioxidants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2015202413A 2014-05-29 2015-05-06 Method for the preparation of human albumin with reduced level of dissolved oxygen Active AU2015202413B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES201430824A ES2524516B1 (es) 2014-05-29 2014-05-29 Procedimiento de preparación de albúmina humana con nivel de oxígeno disuelto reducido
ES201430824 2014-05-29

Publications (2)

Publication Number Publication Date
AU2015202413A1 AU2015202413A1 (en) 2015-12-17
AU2015202413B2 true AU2015202413B2 (en) 2017-08-31

Family

ID=52003454

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015202413A Active AU2015202413B2 (en) 2014-05-29 2015-05-06 Method for the preparation of human albumin with reduced level of dissolved oxygen

Country Status (22)

Country Link
US (1) US10350274B2 (https=)
EP (1) EP2952203B9 (https=)
JP (3) JP2015224251A (https=)
KR (1) KR101960729B1 (https=)
CN (1) CN105315362B (https=)
AR (1) AR100618A1 (https=)
AU (1) AU2015202413B2 (https=)
BR (1) BR102015012091A8 (https=)
CA (1) CA2890642C (https=)
CL (1) CL2015001446A1 (https=)
ES (2) ES2524516B1 (https=)
HU (1) HUE031823T2 (https=)
IL (1) IL238898B (https=)
MX (1) MX362869B (https=)
MY (1) MY171771A (https=)
NZ (1) NZ708537A (https=)
PL (1) PL2952203T3 (https=)
PT (1) PT2952203T (https=)
RU (1) RU2657578C2 (https=)
SG (1) SG10201504137PA (https=)
TW (1) TWI607018B (https=)
ZA (1) ZA201503539B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2524516B1 (es) * 2014-05-29 2015-03-31 Grifols Worldwide Operations Limited Procedimiento de preparación de albúmina humana con nivel de oxígeno disuelto reducido
EP3995141B1 (en) 2016-04-28 2024-01-03 Alkahest, Inc. Plasma fractions as therapy for thymic cancer
LT3484502T (lt) 2016-08-18 2021-12-10 Alkahest, Inc. Kraujo plazmos frakcijos, kaip su senėjimu susijusio pažinimo sutrikimo gydymo priemonė
MX2019012795A (es) 2017-04-26 2020-02-13 Alkahest Inc Régimen de dosificación para el tratamiento de deterioros cognitivos y motores con plasma de sangre y productos de plasma de sangre.
SG11202100347QA (en) 2018-07-20 2021-02-25 Alkahest Inc Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products
SG11202103696XA (en) 2018-10-26 2021-05-28 Alkahest Inc Use of plasma and plasma fractions for improvement of pain, wound healing, and postoperative recovery
CN109627322A (zh) * 2019-01-07 2019-04-16 中国科学院过程工程研究所 一种从Cohn组分Ⅴ上清中分离纯化人血清白蛋白的方法
AU2020378245A1 (en) 2019-11-04 2022-04-07 Alkahest, Inc. Blood plasma fractions for use in muscle regeneration
CN114746100B (zh) 2019-11-20 2024-10-25 万能溶剂有限公司 用于肝再生的血浆级分
EP4689665A1 (en) 2023-03-29 2026-02-11 Grifols Worldwide Operations Limited Compositions and methods of preparation of blood plasma products with reduced levels of fceriss autoantibodies
CN118166053B (zh) * 2024-03-15 2025-02-07 通化安睿特生物制药股份有限公司 一种制备低o-糖基化水平的重组人白蛋白的方法
WO2025230830A1 (en) 2024-04-29 2025-11-06 Alkahest, Inc. Compositions of blood plasma fractions and their use in treatment of spinal muscular atrophy (sma)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4094965A (en) * 1977-04-01 1978-06-13 New England Nuclear Corporation Diagnostic agents containing albumin and method for making same
SE9301581D0 (sv) * 1993-05-07 1993-05-07 Kabi Pharmacia Ab Protein formulation
JPH07126182A (ja) * 1993-10-27 1995-05-16 Green Cross Corp:The 組換えヒト血清アルブミン製剤の滅菌方法
SE9402119D0 (sv) * 1994-06-16 1994-06-16 Pharmacia Ab Solution
US5766582A (en) * 1994-10-11 1998-06-16 Schering Corporation Stable, aqueous alfa interferon solution formulations
JP4254117B2 (ja) * 2001-03-27 2009-04-15 ニプロ株式会社 アルブミン溶液収容プラスチック容器
DE60234142D1 (de) * 2001-03-27 2009-12-10 Nipro Corp Albuminlösung enthaltender Kunststoffbehälter
JP4225416B2 (ja) * 2001-06-29 2009-02-18 旭化成ファーマ株式会社 タンパク質製剤の安定性を改善する方法
US7252799B2 (en) * 2001-08-31 2007-08-07 Clearant, Inc. Methods for sterilizing preparations containing albumin
ATE342904T1 (de) * 2003-08-28 2006-11-15 Nipro Corp Künstlicher sauerstoffträger und herstellungsverfahren dafür
HRP20120994T1 (hr) * 2006-02-07 2012-12-31 Shire Human Genetic Therapies, Inc. Stabilizirana smjesa glukocerebrozidaze
ES2294976B1 (es) * 2007-11-12 2008-12-16 Grifols, S.A. "procedimiento de obtencion de albumina humana de alta eficacia para su uso en terapia de detoxificacion".
JP5990880B2 (ja) * 2011-08-31 2016-09-14 東レ株式会社 有用タンパク質組成物およびその製造方法
CN102816230B (zh) * 2012-08-27 2014-02-12 同路生物制药股份有限公司 人血白蛋白的制备方法
ES2524516B1 (es) * 2014-05-29 2015-03-31 Grifols Worldwide Operations Limited Procedimiento de preparación de albúmina humana con nivel de oxígeno disuelto reducido

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HAYASHI, T. et al. The importance of sample preservation temperature for analysis of the redox state of human serum albumin. Clinica Chimica Acta. Febrero 2002, Vol. 316, N 1-2, páginas: 175 - 178. *
MARIE, A.-L. et al. Analytica Chimica Acta. Octubre 2013, Vol. 800, páginas 103 - 110. *

Also Published As

Publication number Publication date
MX2015006407A (es) 2015-11-30
US20150343025A1 (en) 2015-12-03
ES2524516B1 (es) 2015-03-31
US20170000855A9 (en) 2017-01-05
KR101960729B1 (ko) 2019-03-21
SG10201504137PA (en) 2015-12-30
CA2890642A1 (en) 2015-11-29
KR20160024348A (ko) 2016-03-04
US10350274B2 (en) 2019-07-16
ZA201503539B (en) 2017-01-25
TW201544510A (zh) 2015-12-01
JP2015224251A (ja) 2015-12-14
EP2952203B9 (en) 2018-03-14
ES2601137T3 (es) 2017-02-14
TWI607018B (zh) 2017-12-01
PT2952203T (pt) 2016-11-23
MX362869B (es) 2019-02-20
RU2015118453A (ru) 2016-12-10
IL238898B (en) 2018-01-31
PL2952203T3 (pl) 2017-02-28
JP2018115210A (ja) 2018-07-26
AR100618A1 (es) 2016-10-19
CN105315362A (zh) 2016-02-10
EP2952203B1 (en) 2016-10-26
EP2952203A1 (en) 2015-12-09
RU2657578C2 (ru) 2018-06-14
ES2524516A1 (es) 2014-12-09
CN105315362B (zh) 2019-10-25
CA2890642C (en) 2019-02-12
AU2015202413A1 (en) 2015-12-17
BR102015012091A8 (pt) 2021-03-16
MY171771A (en) 2019-10-29
NZ708537A (en) 2017-06-30
JP2020111614A (ja) 2020-07-27
HUE031823T2 (en) 2017-08-28
CL2015001446A1 (es) 2016-05-13
BR102015012091A2 (pt) 2016-01-05

Similar Documents

Publication Publication Date Title
AU2015202413B2 (en) Method for the preparation of human albumin with reduced level of dissolved oxygen
CN118203658A (zh) 一种重组抗Claudin18.2全人源单克隆抗体注射液制剂及制备方法
JPS6267032A (ja) 組換ヒトβ―インターフェロンを含有する医薬組成物及びその製造方法
EA025663B1 (ru) Композиции этанерцепта, стабилизированные ионами металлов
JP4798833B2 (ja) 加熱処理工程を含むヒト血清アルブミンの製造方法
Tanabe et al. Denatured human α-defensin attenuates the bactericidal activity and the stability against enzymatic digestion
JPH0381290A (ja) 精製されたアルブミン溶液の製造方法
BR112020001363A2 (pt) formulações de hemopexina
Marmorstein et al. Epithelial permeability factor: a serum protein that condenses actin and opens tight junctions
CA2395587C (en) Method of monomerizing human serum albumin polymers
US20180250368A1 (en) Liquid composition of human albumin for therapeutic use
Arfors et al. Variations in the serum esterases of humans, apes and monkeys
WO2002072135A1 (en) LIQUID INTERFERON α PREPARATIONS FOR INJECTION AND METHOD OF STABILIZING THE SAME
JP4798831B2 (ja) ヒト血清アルブミンのミスホールディングを抑制する方法
WO2024189220A1 (en) Method for the preparation of albumin solutions and uses related thereto and thereof
Vahidzadeh et al. Studies on the interaction of colchicine and human serum albumin by the measurement of zeta-potential
Harrington Age and cataract-related degradation of crystallins in human lenses
CS256710B1 (en) Method of albumin extraction from cohne fraction 4

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ JORQUERA NIETO, JUAN IGNACIO; ORTIZ FERNANDEZ, ANA MARIA AND COSTA RIEROLA, MONTSERRAT

FGA Letters patent sealed or granted (standard patent)